Zafeiris Zafeiriou

TL;DR: This cohort study provides clinically actionable information that could impact treatment decisions for affected individuals and identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF.

TL;DR: Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.

TL;DR: A new class of E26 transformation-specific (ETS)-fusion-negative tumors defined by mutations in epigenetic regulators, as well as alterations in pathways not previously implicated in prostate cancer, such as the spliceosome pathway are identified.

TL;DR: Dan Robinson, Eliezer M. Robinson, Andrea Sboner, Marc Schiffman, David M. Smith, Christine Brennan, Javed Siddiqui, Rohit Mehra, Yu Chen, Dana E. Rathkopf, Michael J. Morris, Stephen B. Solomon, Jeremy C. Tomlins, Kathleen A. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T.

TL;DR: Tumor DNA samples from the blood of 97 patients with castration-resistant prostate cancer were analyzed and found that androgen receptor amplifications were present from the beginning and correlated with abiraterone resistance, suggesting that detection of these amplifications should be useful for identifying abiraton-resistant cancers before starting treatment.